top of page
  • Writer's pictureBerke Search

The Berke Report: CDMO & Manufacturing The Fourth Week of April 2023

Alcami Completes Expansion of cGMP Biostorage Facility in Amherst, NH (contractpharma)

Alcami Corp., a CDMO, has completed the Phase III expansion of its cGMP biostorage facility in Amherst, NH, creating a total of 160,000 ft²of ambient cGMP biostorage capacity with21,000 pallet locations. It is now fully operational to support a variety of cGMP client storage needs. Alcami has also added nearly 10,000 ft³of -20 ˚C cold storage capacity and over 12,000 ft³ of ICH stability storage in Massachusetts.

SamsungBiologics Q1 driven by full capacity utilization (bioprocessintl)

Full utilization across its three plants has enabled the CDMO to report 41%revenue growth in the first quarter, says Samsung Biologics. For the first quarter 2023, contract development manufacturing organization (CDMO) Samsung Biologics reported total revenues of KRW 720.9 billion ($539 million), a 41% increase year-on-year. Net profit for the first three months were KRW 141.8 billion, a slight decrease on Q1 2022’s KRW 146.9 billion, attributed to “the elimination of intercompany transactions” after the acquisition of Samsung Bioepisin January 2022.

Bristol Myers Squibb Strengthens Cell Therapy Capabilities by Adding New U.S. Manufacturing Facility for Viral Vector Production from Novartis (PR)

Expansion of its global cell therapy manufacturing network to enable in-house viral vector production through a U.S.- based manufacturing facility and its operations in Libertyville, Illinois, following the company’s execution of an agreement with Novartis. The facility and its operations have capabilities to produce viral vector for both of Bristol Myers Squibb’s CAR T cell therapies. This development advances the company’s long-term ambitions in cell therapy.

Azzur Group Hosts Groundbreaking for Devens, MA Cleanrooms on Demand Facility (PR)

The Azzur Cleanrooms on Demand™ Devens location is the company's latest cleanroom facility, joining locations in Waltham, MA; Burlington, MA; Vista, CA; and Raleigh, NC. All Azzur locations are selected for their proximity to established or growing life sciences business hotspots where lab space often is at a premium. The Azzur Cleanrooms on Demand™ business model came about in 2015 when Azzur Group's client base in Cambridge encouraged the company to create clean room facilities in locations previously underserved with state-of-the-art GMP manufacturing capabilities. Azzur Group plans to open additional Clean rooms on Demand facilities in locations across the US over the next several years.

BioMarin opens €38m expansion of Cork manufacturing site (rte)

The company has invested €38 million over four years to create a state-of-the-art aseptic production facility. The new facility will manufacture, package and label BioMarin therapies for global distribution. BioMarin continues to be a leader in the biopharmaceutical space and these advances make the Shanbally plant one of a few facilities in Ireland with capabilities for end-to-end commercial drug product manufacturing. Investments at the site have seen production levels increase by as much as 150% for some of the company’s products.

6 views0 comments

Recent Posts

See All

The Berke Report: Medical Device Update

Raises: Presidio Medical™ Announces $72M Equity Fundraising Led by Deerfield (PR) Tampa-based PainTEQ, a medical device company seeking to treat lower back pain, says it has closed on a new round of $

The Berke Report: Clinical and Commercial Updates

Commercial: FDA grants accelerated approval to Sarepta’s Duchenne muscular dystrophy gene therapy. The disease occurs in up to one in every 5,000 newborn males worldwide (pmlive) FDA Approves Pfizer’s


bottom of page